Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
- Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
- Ohio Health Marion Area Physicians — Columbus, Ohio
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Ohio: - Nationwide Children's Hospital — Columbus, Ohio
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Ohio: - Ohio State University — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Ohio: - The Ohio State University- James Cancer Hospital — Columbus, Ohio
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Ohio: - Cleveland Clinic Main Campus /ID# 271292 — Cleveland, Ohio
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in Ohio: - Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in Ohio: - University Hospitals — Cleveland, Ohio
- Dayton Physician Network — Dayton, Ohio
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Ohio: - Case Western Reserve University — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Ohio: - University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Cincinnati Cancer Center-West Chester — West Chester, Ohio
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Ohio: - Case Western Reserve University — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Ohio: - Case Western Reserve University — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Dayton Children's Hospital — Dayton, Ohio
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital — Toledo, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Ohio: - University Hospitals Seidman Cancer Center (Case Western) — Cleveland, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Ohio: - Oncology Hematology Care — Cincinnati, Ohio
Phase 2 Recruiting Industry
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in Ohio: - Cleveland Clinic Foundation — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Ohio: - University of Cincinnati Medical Center — Cincinnati, Ohio
- Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymph…
Sponsor: Dren Bio
NCT ID: NCT05475925
Sites in Ohio: - Dren Investigational Site — Columbus, Ohio
Phase 2 Recruiting Industry
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), a…
Sponsor: Cogent Biosciences, Inc.
NCT ID: NCT04996875
Sites in Ohio: - Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer o…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06561360
Sites in Ohio: - Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in Ohio: - The Ohio State University Wexner Medical Center — Columbus, Ohio